That slump has driven its dividend yield up to more than 5%. While Kenvue stock is down this year, it could soar in 2026.

Johnson & Johnson will spin off its $9.2B orthopedics business into a new company, DePuy Synthes, to focus on faster-growing medtech areas.

Breaking up isn’t so hard to do, after all. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & ...

More than 3,000 U.K. claimants accuse U.S. pharmaceutical giant Johnson & Johnson of knowingly selling asbestos-tainted talcum powder, making them ill.

Johnson & Johnson’s stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate ...

The ruling allows plaintiffs with ovarian cancer to sue more than Johnson & Johnson over its baby powder. U.S. District Judge Michael Shipp largely adopted a 2024 decision by special master Joel ...

The multibillion-dollar corporation is still grappling with lawsuits from more than 62,000 claimants in the US alleging its ...

The case involves a California woman who died from mesothelioma, a rare cancer. Her family claimed Johnson and Johnson’s talc ...